Aging Frailty Clinical Trial
Official title:
A Phase 2b, Randomized, Blinded and Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Longeveron Allogenic Human Mesenchymal Stem Cells Infusion in Patients With Aging Frailty
This is a randomized, placebo-controlled, double-blind, parallel arm, multi-center Phase 2b study.
The objectives of this study are to assess safety and efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) compared to placebo on 1) functional mobility and exercise tolerance, 2) patient-reported physical function, and 3) the inflammatory cytokine biomarker tumor necrosis factor (TNF-alpha). ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06063590 -
A Study to Evaluate Allogenic Bone-Marrow Mesenchymal Stromal Cell Product StromaForte in Aging Frailty Patients
|
Phase 1/Phase 2 | |
Completed |
NCT02982915 -
Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty
|
Phase 1/Phase 2 | |
Completed |
NCT03071835 -
A Comparative Study of Subjects Past Their Final Follow-ON Visit
|
||
Completed |
NCT04314011 -
Clinical Study of Umbilical Cord Mesenchymal Stem Cells Infusion for Aging Frailty
|
Phase 1/Phase 2 |